IBDEI2TR ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,45054,2)
;;=^5009226
;;^UTILITY(U,$J,358.3,45055,0)
;;=L27.0^^170^2245^37
;;^UTILITY(U,$J,358.3,45055,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45055,1,3,0)
;;=3^Skin Eruption,Generalized d/t Drugs/Meds Taken Internally
;;^UTILITY(U,$J,358.3,45055,1,4,0)
;;=4^L27.0
;;^UTILITY(U,$J,358.3,45055,2)
;;=^5009144
;;^UTILITY(U,$J,358.3,45056,0)
;;=L27.1^^170^2245^38
;;^UTILITY(U,$J,358.3,45056,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45056,1,3,0)
;;=3^Skin Eruption,Localized d/t Drugs/Meds Taken Internally
;;^UTILITY(U,$J,358.3,45056,1,4,0)
;;=4^L27.1
;;^UTILITY(U,$J,358.3,45056,2)
;;=^5009145
;;^UTILITY(U,$J,358.3,45057,0)
;;=L51.1^^170^2245^44
;;^UTILITY(U,$J,358.3,45057,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45057,1,3,0)
;;=3^Stevens-Johnson Syndrome
;;^UTILITY(U,$J,358.3,45057,1,4,0)
;;=4^L51.1
;;^UTILITY(U,$J,358.3,45057,2)
;;=^336636
;;^UTILITY(U,$J,358.3,45058,0)
;;=L51.3^^170^2245^45
;;^UTILITY(U,$J,358.3,45058,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45058,1,3,0)
;;=3^Stevens-Johnson Syndrome-Toxic Epdrml Necrolysis Overlap Syndrome
;;^UTILITY(U,$J,358.3,45058,1,4,0)
;;=4^L51.3
;;^UTILITY(U,$J,358.3,45058,2)
;;=^336637
;;^UTILITY(U,$J,358.3,45059,0)
;;=Z12.83^^170^2245^21
;;^UTILITY(U,$J,358.3,45059,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45059,1,3,0)
;;=3^Screening for Malig Neop of Skin
;;^UTILITY(U,$J,358.3,45059,1,4,0)
;;=4^Z12.83
;;^UTILITY(U,$J,358.3,45059,2)
;;=^5062696
;;^UTILITY(U,$J,358.3,45060,0)
;;=Z48.817^^170^2245^48
;;^UTILITY(U,$J,358.3,45060,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45060,1,3,0)
;;=3^Surgical Aftercare Following Skin Surgery
;;^UTILITY(U,$J,358.3,45060,1,4,0)
;;=4^Z48.817
;;^UTILITY(U,$J,358.3,45060,2)
;;=^5063054
;;^UTILITY(U,$J,358.3,45061,0)
;;=L94.0^^170^2245^20
;;^UTILITY(U,$J,358.3,45061,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45061,1,3,0)
;;=3^Scleroderma,Localized
;;^UTILITY(U,$J,358.3,45061,1,4,0)
;;=4^L94.0
;;^UTILITY(U,$J,358.3,45061,2)
;;=^5009470
;;^UTILITY(U,$J,358.3,45062,0)
;;=D23.9^^170^2245^22
;;^UTILITY(U,$J,358.3,45062,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45062,1,3,0)
;;=3^Sebaceous Hyperplasia
;;^UTILITY(U,$J,358.3,45062,1,4,0)
;;=4^D23.9
;;^UTILITY(U,$J,358.3,45062,2)
;;=^5002076
;;^UTILITY(U,$J,358.3,45063,0)
;;=L21.9^^170^2245^23
;;^UTILITY(U,$J,358.3,45063,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45063,1,3,0)
;;=3^Seborrhea,Unspec
;;^UTILITY(U,$J,358.3,45063,1,4,0)
;;=4^L21.9
;;^UTILITY(U,$J,358.3,45063,2)
;;=^188703
;;^UTILITY(U,$J,358.3,45064,0)
;;=L91.8^^170^2245^39
;;^UTILITY(U,$J,358.3,45064,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45064,1,3,0)
;;=3^Skin Tag
;;^UTILITY(U,$J,358.3,45064,1,4,0)
;;=4^L91.8
;;^UTILITY(U,$J,358.3,45064,2)
;;=^5009460
;;^UTILITY(U,$J,358.3,45065,0)
;;=I83.12^^170^2245^43
;;^UTILITY(U,$J,358.3,45065,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45065,1,3,0)
;;=3^Stasis Dermatitis.Left Leg
;;^UTILITY(U,$J,358.3,45065,1,4,0)
;;=4^I83.12
;;^UTILITY(U,$J,358.3,45065,2)
;;=^5007989
;;^UTILITY(U,$J,358.3,45066,0)
;;=I83.11^^170^2245^42
;;^UTILITY(U,$J,358.3,45066,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,45066,1,3,0)
;;=3^Stasis Dermatitis,Right Leg
;;^UTILITY(U,$J,358.3,45066,1,4,0)
;;=4^I83.11
;;^UTILITY(U,$J,358.3,45066,2)
;;=^5007988
;;^UTILITY(U,$J,358.3,45067,0)
;;=C84.19^^170^2245^26
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI2TR 3797 printed Dec 13, 2024@02:35:40 Page 2
IBDEI2TR ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,45054,2)
+2 ;;=^5009226
+3 ;;^UTILITY(U,$J,358.3,45055,0)
+4 ;;=L27.0^^170^2245^37
+5 ;;^UTILITY(U,$J,358.3,45055,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,45055,1,3,0)
+8 ;;=3^Skin Eruption,Generalized d/t Drugs/Meds Taken Internally
+9 ;;^UTILITY(U,$J,358.3,45055,1,4,0)
+10 ;;=4^L27.0
+11 ;;^UTILITY(U,$J,358.3,45055,2)
+12 ;;=^5009144
+13 ;;^UTILITY(U,$J,358.3,45056,0)
+14 ;;=L27.1^^170^2245^38
+15 ;;^UTILITY(U,$J,358.3,45056,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,45056,1,3,0)
+18 ;;=3^Skin Eruption,Localized d/t Drugs/Meds Taken Internally
+19 ;;^UTILITY(U,$J,358.3,45056,1,4,0)
+20 ;;=4^L27.1
+21 ;;^UTILITY(U,$J,358.3,45056,2)
+22 ;;=^5009145
+23 ;;^UTILITY(U,$J,358.3,45057,0)
+24 ;;=L51.1^^170^2245^44
+25 ;;^UTILITY(U,$J,358.3,45057,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,45057,1,3,0)
+28 ;;=3^Stevens-Johnson Syndrome
+29 ;;^UTILITY(U,$J,358.3,45057,1,4,0)
+30 ;;=4^L51.1
+31 ;;^UTILITY(U,$J,358.3,45057,2)
+32 ;;=^336636
+33 ;;^UTILITY(U,$J,358.3,45058,0)
+34 ;;=L51.3^^170^2245^45
+35 ;;^UTILITY(U,$J,358.3,45058,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,45058,1,3,0)
+38 ;;=3^Stevens-Johnson Syndrome-Toxic Epdrml Necrolysis Overlap Syndrome
+39 ;;^UTILITY(U,$J,358.3,45058,1,4,0)
+40 ;;=4^L51.3
+41 ;;^UTILITY(U,$J,358.3,45058,2)
+42 ;;=^336637
+43 ;;^UTILITY(U,$J,358.3,45059,0)
+44 ;;=Z12.83^^170^2245^21
+45 ;;^UTILITY(U,$J,358.3,45059,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,45059,1,3,0)
+48 ;;=3^Screening for Malig Neop of Skin
+49 ;;^UTILITY(U,$J,358.3,45059,1,4,0)
+50 ;;=4^Z12.83
+51 ;;^UTILITY(U,$J,358.3,45059,2)
+52 ;;=^5062696
+53 ;;^UTILITY(U,$J,358.3,45060,0)
+54 ;;=Z48.817^^170^2245^48
+55 ;;^UTILITY(U,$J,358.3,45060,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,45060,1,3,0)
+58 ;;=3^Surgical Aftercare Following Skin Surgery
+59 ;;^UTILITY(U,$J,358.3,45060,1,4,0)
+60 ;;=4^Z48.817
+61 ;;^UTILITY(U,$J,358.3,45060,2)
+62 ;;=^5063054
+63 ;;^UTILITY(U,$J,358.3,45061,0)
+64 ;;=L94.0^^170^2245^20
+65 ;;^UTILITY(U,$J,358.3,45061,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,45061,1,3,0)
+68 ;;=3^Scleroderma,Localized
+69 ;;^UTILITY(U,$J,358.3,45061,1,4,0)
+70 ;;=4^L94.0
+71 ;;^UTILITY(U,$J,358.3,45061,2)
+72 ;;=^5009470
+73 ;;^UTILITY(U,$J,358.3,45062,0)
+74 ;;=D23.9^^170^2245^22
+75 ;;^UTILITY(U,$J,358.3,45062,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,45062,1,3,0)
+78 ;;=3^Sebaceous Hyperplasia
+79 ;;^UTILITY(U,$J,358.3,45062,1,4,0)
+80 ;;=4^D23.9
+81 ;;^UTILITY(U,$J,358.3,45062,2)
+82 ;;=^5002076
+83 ;;^UTILITY(U,$J,358.3,45063,0)
+84 ;;=L21.9^^170^2245^23
+85 ;;^UTILITY(U,$J,358.3,45063,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,45063,1,3,0)
+88 ;;=3^Seborrhea,Unspec
+89 ;;^UTILITY(U,$J,358.3,45063,1,4,0)
+90 ;;=4^L21.9
+91 ;;^UTILITY(U,$J,358.3,45063,2)
+92 ;;=^188703
+93 ;;^UTILITY(U,$J,358.3,45064,0)
+94 ;;=L91.8^^170^2245^39
+95 ;;^UTILITY(U,$J,358.3,45064,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,45064,1,3,0)
+98 ;;=3^Skin Tag
+99 ;;^UTILITY(U,$J,358.3,45064,1,4,0)
+100 ;;=4^L91.8
+101 ;;^UTILITY(U,$J,358.3,45064,2)
+102 ;;=^5009460
+103 ;;^UTILITY(U,$J,358.3,45065,0)
+104 ;;=I83.12^^170^2245^43
+105 ;;^UTILITY(U,$J,358.3,45065,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,45065,1,3,0)
+108 ;;=3^Stasis Dermatitis.Left Leg
+109 ;;^UTILITY(U,$J,358.3,45065,1,4,0)
+110 ;;=4^I83.12
+111 ;;^UTILITY(U,$J,358.3,45065,2)
+112 ;;=^5007989
+113 ;;^UTILITY(U,$J,358.3,45066,0)
+114 ;;=I83.11^^170^2245^42
+115 ;;^UTILITY(U,$J,358.3,45066,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,45066,1,3,0)
+118 ;;=3^Stasis Dermatitis,Right Leg
+119 ;;^UTILITY(U,$J,358.3,45066,1,4,0)
+120 ;;=4^I83.11
+121 ;;^UTILITY(U,$J,358.3,45066,2)
+122 ;;=^5007988
+123 ;;^UTILITY(U,$J,358.3,45067,0)
+124 ;;=C84.19^^170^2245^26
